FDA approves new drug for ALS treatment

FDA approves new drug for ALS treatment

The U.S. Food & Drug Administration (FDA) has finally given its approval for a new drug for the treatment of amyotrophic lateral sclerosis (ALS).

The federal agency announced that Radicava, which is also known as edaravone, has been approved for the treatment of ALS in the United States. The only other drug tthat is available iin the nation specifically for the treatment of condition is riluzole.

Various tests carried out in Japan found that ALS patients who received Radicava experienced a slighter decline in their levels of daily functioning as compared with those who were given a placebo.

The maker of the newly-approved drug, MT Pharma, said that Radicava slowed the decline of the patients’ physical function by 33 per cent.

Eric Bastings, deputy director of the neurology products division at the FDA, said, “This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option.”

Radicava is the first drug to be approved by the FDA for the treatment of ALS in more than two decades. Riluzole was approved for treating the condition in 1995.